Two posters presented at the North American Neuroendocrine Tumor Society (NANETS) annual meeting, October 4-6 in Seattle, Washington, lend support to the idea of targeted treatment for neuroendocrine tumors.
Two posters presented at the North American Neuroendocrine Tumor Society annual meeting, October 4-6 in Seattle, Washington, lend support to the idea of targeted treatment for neuroendocrine tumors.
The first abstract, presented by researchers from the University of California, San Francisco (UCSF), conducted a chart review of 56 patients with grade 3 extrapulmonary neuroendocrine carcinoma (EP-NEC).1 Given the lack of sufficient knowledge on the optimal treatment options for high-grade EP-NEC, researchers are searching for biomarker-based leads to guide treatment decisions. For this study, a retrospective chart review of 56 patients with grade 3 EP-NEC whose tumors had been analyzed for actionable mutations.
The average diagnosis age among the 56 cases was 58.5 years, and this included 20 colorectal cancer, 14 pancreatic cancer, 6 other gastrointestinal cancer, and 16 other NECs. The majority of the patients (n = 30) were male.
While 7 genomic alterations were observed in over 15% of primary tumors, RB1 and TP53 were the only ones to cross the 15% threshold in every group. Actionable mutations were identified in 8 patient samples and an additional 6 tumor samples expressed gene variants with potential therapeutic implications for approved therapies (TSC1, PTEN, RET, HRAS, PTCH1, CDK4, and AKT2). Of the 25 tumor samples that were identified to have microsatellite instability (MSI), 1 sample was MSI-high.
Based on these findings, the authors concluded that commercial genomic platforms (Foundation One in this case) can prove vital in identifying potential therapeutic targets in patients with grade 3 EP-NEC.
The second poster, also by the authors of the first abstract, reported on a retrospective analysis on a different set of tumor samples, this time from 236 patients with neuroendocrine tumors who were referred to UCSF’s Cancer Genetics and Prevention Program between 2004 and 2017.2 Nearly 60% (n = 139) of those patients followed up with genetic counseling, with the probability being higher if the patient had at least 1 family member diagnosed with cancer. In the subgroup of 107 patients who underwent genetic testing, pancreatic neuroendocrine tumors were more associated with testing (odds ratio [OR], 0.15; P = .001). Prior to 2015, single-gene tests were common, after which 130-gene panels took over.
There was no significant difference between single versus multi-gene testing in differentiating between pathogenic or likely pathogenic mutations that were identified in 29% of patients (31/107). Functional tumors were statistically more likely to show a lower rate of pathogenic/likely pathogenic mutations thank non-functional tumors (OR, .17; P = .037).
The authors conclude that while their analysis underscored the value of multigene panels in detecting rare mutations in neuroendocrine tumors, the fact that only about 60% of patients followed up with genetic counseling means barriers to testing continue to exist.
References
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More